Hepatic arterial infusion pump chemotherapy

Our programme

The Erasmus MC Cancer Institute in Rotterdam, the Netherlands, has started a new program on Hepatic Arterial Infusion Pump (HAIP) chemotherapy for patients with liver tumors. In close collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC) the program will start with the PUMP trial. The PUMP trial focusses on patients with resectable colorectal liver metastases. In the near future our programme will be extended for patients with primary liver tumors (intrahepatic cholangocarcinoma).

Hepatic Arterial Infusion Pump chemotherapy

HAIP chemotherapy has been developed in the Memorial Sloan Kettering Cancer Center, and safely conducted for many years. HAIP chemotherapy involves continues infusion of intra-arterial chemotherapy using an implanted pump. Side-effects are uncommon since the chemotherapy has local effect in the liver. HAIP chemotherapy has been developed Dr. N. Kemeny, medical oncologist at MSKCC, and has been used for many years both for patients with surgically resected liver metastases (adjuvant). The effect of HAIP chemotherapy is a reduction of the recurrence of the cancer in the liver and consequently improved survival in good quality of life. Secondly, HAIP chemotherapy can be used in patients with unresectable colorectal liver metastases. In this case, the aim is to prolong survival with good quality of life or, if possible, tumor shrinkage to a resectable state.

Availability and PUMP trial

Despite promising results HAIP chemotherapy is not generally available yet. A final trial should definitively prove the benefit. The PUMP study group has developed the PUMP trial for patients with resectable colorectal liver metastases.

Contact information

 pump@erasmusmc.nl
Erasmus MC Cancer Institute
Dr. Molewaterplein 40
3015 GD Rotterdam
The Netherlands

Programme directors

B. Groot Koerkamp, MD, PhD
Surgical Oncologist
Erasmus MC Cancer Institute

Professor C. Verhoef, MD, PhD
Surgical Oncologist
Head of the Department of Surgical Oncology and Gastro-enterology

Coordinating investigator

F.E. Buisman, MD
Trial coordinator
Erasmus MC Cancer Institute

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo